Patients with clinically relevant medical history, including autoimmune disease, cardiovascular disease, hepatic disease or bleeding disorders
Subjects with clinically significant cardiovascular disease, including:
Significant active cardiovascular or pulmonary disease including:
Current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular, pulmonary, or renal disease) other than cancer
Significant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including:
Patients with a significant cardiovascular disease or condition, including:
Patients with a significant cardiovascular disease or condition, including:
Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
Clinically significant cardiovascular disease including:
Have significant, uncontrolled, or active cardiovascular disease, including, but not restricted to:
Subject has significant cardiovascular disease, including:
Significant cardiovascular disease including Congestive Heart Failure or poorly controlled hypertension.
Impaired cardiovascular function or clinically significant cardiovascular disease including any of the following: symptomatic congestive heart failure, clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except for atrial fibrillation and paroxysmal supraventricular tachycardia
Significant cardiovascular disease (including congestive heart failure).
Significant active cardiovascular or pulmonary disease including:
Subject has clinically significant cardiovascular disease including:
Patient has uncontrolled or significant cardiovascular disease, including:
Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
Uncontrolled or significant cardiovascular disease, including:
History of clinically significant cardiovascular disease including.
Significant cardiovascular disease including CHF, leptomeningeal disease, poorly controlled hypertension, or an MI within 6 months prior to dosing.
History of clinically significant cardiovascular disease including:
Clinically significant cardiovascular disease at screening including:
Significant cardiovascular disease including CHF or poorly controlled hypertension.
Significant cardiovascular disease including CHF or poorly controlled hypertension.
Uncontrolled or significant cardiovascular disease, including:
Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following: symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
Patients with a significant cardiovascular disease or condition, including:
Patients with a significant cardiovascular disease or condition, including:
Clinically significant cardiovascular disease including:
Current severe, uncontrolled systemic disease (including but not limited to clinically significant cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding the cancer under study
Patient has uncontrolled or significant cardiovascular disease, including:
Patients with malnutrition, active infection, significant pulmonary disease and cardiovascular disease as determined by the physician as they could impact fatigue
Uncontrolled or significant cardiovascular disease, including any of the following:
Significant cardiovascular disease including CHF or poorly controlled hypertension.
Clinically significant cardiovascular disease including:
